Molecular interaction of Acetylcholinesterase with Carnosic acid derivatives: A neuroinformatics study

CNS and Neurological Disorders - Drug Targets

Volumn 13, Issue 3, 2014, Pages 440-446

  Merad, M ^a   Soufi, W ^a   Ghalem, S ^a   Boukli, F ^a   Baig, M H ^b   Ahmad, K ^b   Kamal, Mohammad A ^c  

^a UNIVERSITY OF TLEMCEN   (Algeria)

^b INTEGRAL UNIVERSITY   (India)

^c KING ABDULAZIZ UNIVERSITY   (Saudi Arabia)

Author keywords

Acetylcholinesterase; Carnosic acid derivatives; Docking

Indexed keywords

CARNOSIC ACID; CHOLINESTERASE INHIBITOR; ABIETANE DERIVATIVE; ACETYLCHOLINE; ACETYLCHOLINESTERASE; ANTIOXIDANT; PLANT EXTRACT; SALVIN;

ARTICLE; BINDING AFFINITY; CHEMICAL PHENOMENA; COMPUTER ANALYSIS; CRYSTAL STRUCTURE; GEOMETRY; MOLECULAR DOCKING; MOLECULAR INTERACTION; PROCESS OPTIMIZATION; SCORING SYSTEM; X RAY ANALYSIS; ALZHEIMER DISEASE; ANIMAL; BIOLOGY; CHEMICAL STRUCTURE; CHEMISTRY; COGNITION DISORDERS; COMPLICATION; COMPUTER SIMULATION; DEFICIENCY; GENETICS; HUMAN; METABOLISM;

ACETYLCHOLINE; ACETYLCHOLINESTERASE; ALZHEIMER DISEASE; ANIMALS; ANTIOXIDANTS; COGNITION DISORDERS; COMPUTATIONAL BIOLOGY; COMPUTER SIMULATION; DITERPENES, ABIETANE; HUMANS; MODELS, MOLECULAR; PLANT EXTRACTS;

EID: 84904471613     PISSN: 18715273     EISSN: 19963181     Source Type: Journal    
DOI: 10.2174/18715273113126660157     Document Type: Article

References (34)

1. Al-Jafari AA, Kamal MA, Greig NH, Alhomida AS, Perry E. Kinetics of human erythrocyte acetylcholinesterase inhibition by a novel derivative of physostigmine: Phenserine. Biochem Biophys Res Comm 1998; 248(1): 180-5.
2. Silman I, Sussman JL. Acetylcholinesterase: how is structure related to function. Chem Biol Interact 2008; 175(1-3): 3-10.
3. Jin QH, Shi YF, He HY, et al. Isolation of acetylcholinesterase from apoptotic human lung fibroblast cells by antibody affinity chromatography. Biotechniques 2002; 92-4: 96-7.
4. Sussman JL, Harel M, Silman I. Three-dimensional structure of acetylcholinesterase and of its complexes with anticholinesterase drugs. Chem Biol Interact 1993; 87: 187-97.
5. Kamal MA, Al-Jafari AA. graphical kinetic analysis model for the inhibition of acetylcholinesterase by anti-Alzheimer's drug, tacrine S. J Biol Sci 2001; 8(2): 113-22.
6. Kamal MA, Greig NH, Alhomida AS, Al-Jafari AA. Kinetics of human acetylcholinesterase inhibition by novel experimental Alzheimer therapeutic agent, tolserine. Biochem Pharmacol 2000; 60(4): 561-70.
7. Shakil S, Kamal MA, Tabrez S, et al. Molecular interaction of the antineoplastic drug, methotrexate with human brain acetylcholinesterase: a docking study. CNS Neurol Disord Drug Targets 2012; 11(2): 142-7.
8. Inestrosa NC, Perelman A. Distribution and anchoring of the molecular forms of Acetylcholinesterase. Trends Pharmacol Sci 1989; 10: 325-9.
9. Masters CL, Simms G, Weinman NA, et al. Amyloid plaque protein in Alzheimer disease and Down's syndrome. Proc Natl Acad Sci USA 1985; 82: 4245-9.
10. Inestrosa NC, Roberts WL, Marshall TD, Rosenberry TL. Acetylcholinesterase fi-om bovine caudate nucleus is attached to membranes by a novel subunit distinct from those of acetylchoKnesterases in other tissues. J Biol Chem 1987; 262: 4441-4.
11. Alvarez A, Alarcon R, Opazo C, et al. Stable complexes involving acetylcholinesterase and amyloid-b peptide change the biochemical properties of the enzyme and increase the neurotoxicity of Alzheimer's fibrils. Neuroscience 1998; 18: 3213-23.
12. Davies P, Maloney AJ. Selective loss of central cholinergic neurons in Alzheimer's disease. Lancet 1976; 2: 1403.
13. Hodges JR. Alzheimer's centennial legacy: origins, landmarks and the current status of knowledge concerning cognitive aspects. Brain 2006; 129: 2811-22.
14. Ji HF, Li XJ, Zhang HY. Natural products and drug discovery. EMBO Rep 2009; 10.3: 194-200.
15. Adams M, Gmünder F, Hamburger M. Plants traditionally used in age related brain disorders-A survey of ethnobotanical literature. J Ethnopharmacol 2007; 113(3): 363-81.
16. Mange A, Nishida N, Milhavet O, et al. Amphotericin B inhibits the generation of the scrapie isoform of the prion protein in infected cultures. J Virol 2000; 74: 3135-40.
17. Kosaka K, Mimura J, Itoh K, et al. Role of Nrf2 and p62/ZIP in the neurite outgrowth by carnosic acid in PC12h cells. J Biochem 2010; 147: 73-81.
18. Schapira M, Raaka BM, Samuels HH, Abagyan R. Rational discovery of novel nuclear hormone receptor antagonists. Proc Natl Acad Sci USA 2000; 97: 1008-13.
19. Wang X, Richards NGJ. Computer-based strategy for modeling the interaction of AGRP and related peptide ligands with the AGRPbinding site of murine melanocortin receptors. Curr Pharm Des 2005; 11: 345-56.
20. Colmenarejo G. In Silico ADME Prediction: Data Sets and Models. Curr Comput Aided Drug Des 2005; 1: 365-76.
21. Jennings A, Tennant M. Discovery strategies in a BioPharmaceutical startup: maximising your chances of success using computational filters. Curr Pharm Des 2005; 11: 335-44.
22. Kalyanaraman C, Bernacki K, Jacobson MP. Virtual screening against highly charged active sites: identifying substrates of alphabeta barrel enzymes. Biochemistry 2005; 44:2059-71.
23. Case DA, Pearlman DA, Caldwell JW, et al. AMBER 99. University of California; San Francisco 1999.
24. Jones G, Willett P, Glen RC. Molecular recognition of receptor sites using a genetic algorithim with a description of desolvation. J Mol Biol 1995; 245: 43-53.
25. Wang R, Lai L, Wang S. Further development and validation of empirical scoring functions for structure-based binding affinity prediction. J Comput Aided Mol Des 2002; 16: 11-26.
26. Goodsell DS, Morris GM, Olson AJ. Automated docking of flexible ligands: applications of AutoDock. J Mol Recog 1998; 9: 1-5.
27. Silman I, Sussman JL. Acetylcholinesterase: how is structure related to function. Chem Biol Interact 2008; 175: 3-10.
28. Darvesh S, Hopkins DA, Geula C. Neurobiology of butyrylcholinesterase. Nat Rev Neurosci 2003; 4: 131-8.
29. Silman I, Sussman JL. Acetylcholinesterase: 'classical' and 'nonclassical' functions and pharmacology. Curr Opin Pharmacol 2005; 5(3): 293-302.
30. Botti SA, Felder CE, Lifson S, Sussman JL, Silman I. A modular treatment of molecular traffic through the active site of cholinesterase. Biophys J 1999; 77: 2430-50.
31. Sussman JL, Harel M, Frolow F, et al. Atomic structure of acetylcholinesterase from Torpedo californica: a prototypic acetylcholine-binding protein. Science 1991; 253: 872-9.
32. Kua J, Zhang Y, Eslami AC, Butler JR, McCammon J. A Studying the roles of W86: E202: and Y337 in binding of acetylcholine to acetylcholinesterase using a combined molecular dynamics and multiple docking approach. Protein Sci 2003; 12(12): 2675-84.
33. Shafferman A, Velan B, Ordentlich A, et al. Substrate inhibition of acetylcholinesterase: residues affecting signal transduction from the surface to the catalytic center. EMBO J 1992; 11(10): 3561.
34. El Omri A, Han J, Yamada P, et al. Rosmarinus officinalis polyphenols activate cholinergic activities in PC12 cells through phosphorylation of ERK1/2. Ethnopharmacology 2010; 131(2): 451-8.